Olaf Heidenreich

8.9k total citations
136 papers, 4.1k citations indexed

About

Olaf Heidenreich is a scholar working on Molecular Biology, Hematology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Olaf Heidenreich has authored 136 papers receiving a total of 4.1k indexed citations (citations by other indexed papers that have themselves been cited), including 92 papers in Molecular Biology, 63 papers in Hematology and 23 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Olaf Heidenreich's work include Acute Myeloid Leukemia Research (53 papers), RNA Interference and Gene Delivery (31 papers) and Protein Degradation and Inhibitors (27 papers). Olaf Heidenreich is often cited by papers focused on Acute Myeloid Leukemia Research (53 papers), RNA Interference and Gene Delivery (31 papers) and Protein Degradation and Inhibitors (27 papers). Olaf Heidenreich collaborates with scholars based in United Kingdom, Germany and Netherlands. Olaf Heidenreich's co-authors include F. Eckstein, Michael Nerenberg, Josef Vormoor, Alfred Nordheim, Arnold Ganser, Simon Bomken, Xin Xu, Shin Hyeok Kang, Gerhard Schratt and David A. Brown and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nucleic Acids Research and Journal of Biological Chemistry.

In The Last Decade

Olaf Heidenreich

129 papers receiving 4.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Olaf Heidenreich United Kingdom	36	3.0k	1.1k	613	609	491	136	4.1k
Misao Ohki Japan	37	3.1k 1.0×	1.3k 1.2×	606 1.0×	337 0.6×	527 1.1×	79	4.3k
Eric R. Lechman Canada	25	2.2k 0.7×	827 0.8×	673 1.1×	799 1.3×	737 1.5×	55	3.8k
Linda H. Shapiro United States	34	2.0k 0.7×	381 0.4×	1.6k 2.5×	633 1.0×	587 1.2×	69	4.3k
Peter N. Cockerill United Kingdom	37	3.4k 1.1×	566 0.5×	467 0.8×	1.2k 2.0×	582 1.2×	90	4.6k
Rolf Marschalek Germany	40	3.3k 1.1×	2.0k 1.8×	569 0.9×	395 0.6×	412 0.8×	225	5.4k
Dennis D. Hickstein United States	33	2.0k 0.7×	1.1k 1.0×	423 0.7×	1.1k 1.8×	260 0.5×	118	3.9k
Yoshinobu Matsuo Japan	33	1.7k 0.6×	972 0.9×	940 1.5×	1.0k 1.7×	346 0.7×	126	3.7k
Michael Morgan Germany	32	2.5k 0.8×	2.2k 2.0×	1.5k 2.4×	1.0k 1.7×	500 1.0×	106	5.0k
Scott A. Ness United States	34	2.5k 0.8×	399 0.4×	982 1.6×	992 1.6×	635 1.3×	85	4.0k
James C. Mulloy United States	41	4.0k 1.3×	2.5k 2.3×	1.3k 2.1×	2.0k 3.2×	677 1.4×	114	6.7k

Countries citing papers authored by Olaf Heidenreich

Since Specialization

Citations

This map shows the geographic impact of Olaf Heidenreich's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Olaf Heidenreich with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Olaf Heidenreich more than expected).

Fields of papers citing papers by Olaf Heidenreich

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Olaf Heidenreich. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Olaf Heidenreich. The network helps show where Olaf Heidenreich may publish in the future.

Co-authorship network of co-authors of Olaf Heidenreich

This figure shows the co-authorship network connecting the top 25 collaborators of Olaf Heidenreich. A scholar is included among the top collaborators of Olaf Heidenreich based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Olaf Heidenreich. Olaf Heidenreich is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zwaan, C. Michel, Anja Krippner‐Heidenreich, Constanze Bonifer, et al.. (2025). Fusion gene depletion eliminates stemness and induces bidirectional differentiation of acute myeloid leukemia. Blood. 146(24). 2963–2978.

Nasrullah, Mohammad, K Bahadur, Cezary Kucharski, et al.. (2025). Suppressing t(4;11) Acute Leukemia by Lipopolymer Nanoparticle Delivery of siRNA Targeting KMT2A::AFF1 with Enhanced Extrahepatic Delivery. Advanced Healthcare Materials. 14(27). e02019–e02019.

Steinebach, Christian, et al.. (2025). PROTAC-Mediated GSPT1 Degradation Impairs the Expression of Fusion Genes in Acute Myeloid Leukemia. Cancers. 17(2). 211–211. 1 indexed citations

Coleman, Daniel, Peter Keane, Paulynn Suyin Chin, et al.. (2024). Pharmacological inhibition of RAS overcomes FLT3 inhibitor resistance in FLT3-ITD+ AML through AP-1 and RUNX1. iScience. 27(4). 109576–109576. 7 indexed citations

Bergevoet, Saskia M., Pascal W.T.C. Jansen, Anja Krippner‐Heidenreich, et al.. (2024). HMX3 is a critical vulnerability in MECOM-negative KMT2A::MLLT3 acute myelomonocytic leukemia. Leukemia. 39(2). 371–380. 2 indexed citations

Blair, Helen J., Anthony V. Moorman, Olaf Heidenreich, et al.. (2024). Combination p53 activation and BCL-xL/BCL-2 inhibition as a therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia. Leukemia. 38(6). 1223–1235. 8 indexed citations

Zhang, Heyang, et al.. (2024). Optimization of Targeted Lipid Nanoparticle for the Treatment of RUNX1::ETO Driven AML. Blood. 144(Supplement 1). 2199–2199. 1 indexed citations

Meringa, Angelo D., Ronald W. Stam, Rishi S. Kotecha, et al.. (2024). Combining CRISPR-Cas9 and TCR exchange to generate a safe and efficient cord blood-derived T cell product for pediatric relapsed AML. Journal for ImmunoTherapy of Cancer. 12(4). e008174–e008174. 3 indexed citations

Fens, Marcel H.A.M., Ryan Nelson, Anja Krippner‐Heidenreich, et al.. (2023). Increased Bone Marrow Uptake and Accumulation of Very-Late Antigen-4 Targeted Lipid Nanoparticles. Pharmaceutics. 15(6). 1603–1603. 16 indexed citations

10.

Sinclair, Paul, Prahlad V. Raninga, Sarra Ryan, et al.. (2023). Disruption to the FOXO-PRDM1 axis resulting from deletions of chromosome 6 in acute lymphoblastic leukaemia. Leukemia. 37(3). 636–649. 4 indexed citations

11.

Marín‐Rubio, José Luis, Rachel E. Heap, María Emilia Dueñas, et al.. (2022). A Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Assay Identifies Nilotinib as an Inhibitor of Inflammation in Acute Myeloid Leukemia. Journal of Medicinal Chemistry. 65(18). 12014–12030. 7 indexed citations

12.

Potluri, Sandeep, Salam A. Assi, Paulynn Suyin Chin, et al.. (2021). Isoform-specific and signaling-dependent propagation of acute myeloid leukemia by Wilms tumor 1. Cell Reports. 35(3). 109010–109010. 14 indexed citations

13.

Bertram, Stefanie, Helen Blair, Verena Börger, et al.. (2020). Exposure of Patient-Derived Mesenchymal Stromal Cells to TGFB1 Supports Fibrosis Induction in a Pediatric Acute Megakaryoblastic Leukemia Model. Molecular Cancer Research. 18(10). 1603–1612. 2 indexed citations

14.

Dallmann, Iris, Andreas Pich, Jan Hegermann, et al.. (2019). Stable depletion of RUNX1-ETO in Kasumi-1 cells induces expression and enhanced proteolytic activity of Cathepsin G and Neutrophil Elastase. PLoS ONE. 14(12). e0225977–e0225977. 3 indexed citations

15.

Duque‐Afonso, Jesús, et al.. (2011). The HDAC class I-specific inhibitor entinostat (MS-275) effectively relieves epigenetic silencing of the LAT2 gene mediated by AML1/ETO. Oncogene. 30(27). 3062–3072. 38 indexed citations

16.

Dunne, Jenny, Duncan M. Gascoyne, T. Andrew Lister, et al.. (2010). AML1/ETO Proteins Control POU4F1/BRN3A Expression and Function in t(8;21) Acute Myeloid Leukemia. Cancer Research. 70(10). 3985–3995. 11 indexed citations

17.

Walker, Tobias, et al.. (2005). Suppression of ICAM-1 in human venous endothelial cells by small interfering RNAs. European Journal of Cardio-Thoracic Surgery. 28(6). 816–820. 17 indexed citations

18.

Nagel, Stefan, Lothar Hambach, Jürgen Krauter, et al.. (2002). Analysis of the Nuclear Distribution of the Translocation t(8;21)-Derived Fusion Protein AML1/ETO by Confocal Laser Scanning Microscopy. Journal of Hematotherapy & Stem Cell Research. 11(2). 401–408. 3 indexed citations

19.

Heidenreich, Olaf, Xiao Xu, & Michael Nerenberg. (1996). A Hammerhead Ribozyme Cleaves Its Target RNA During RNA Preparation. Antisense and Nucleic Acid Drug Development. 6(2). 141–144. 11 indexed citations

20.

Xu, Xin‐Jian, Olaf Heidenreich, Isao Kitajima, et al.. (1996). Constitutively activated JNK is associated with HTLV-1 mediated tumorigenesis.. PubMed. 13(1). 135–42. 78 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact